Related Experiment Video
Updated: Aug 7, 2026
09:16
Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury
Published on: June 21, 2019
Lacosamide Use After Traumatic Brain Injury: A Scoping Review
Hiroaki Taniguchi1, Seigo Yamada2
1Department of Internal Medicine, Nishiguchicho Shin-ai Clinic, Toyohashi, JPN.
Cureus
|August 6, 2026
Summary
Lacosamide (LCM) shows limited evidence for acute traumatic brain injury (TBI) use. Research is needed to clarify its efficacy for seizure control and neuroprotection in TBI patients.
Area of Science:
- Neuroscience
- Pharmacology
- Trauma Research
Background:
- Lacosamide (LCM) is an antiepileptic drug with potential neuroprotective mechanisms.
- Its efficacy in traumatic brain injury (TBI) management remains largely uncharacterized.
Purpose of the Study:
- To review and characterize preclinical and clinical research on Lacosamide (LCM) in acute traumatic brain injury (TBI).
- To evaluate LCM's role in seizure prophylaxis, treatment, and potential neuroprotective effects post-TBI.
Main Methods:
- A comprehensive scoping review of multiple databases (MEDLINE, CENTRAL, CINAHL, Web of Science, ClinicalTrials.gov).
- Inclusion of preclinical TBI models and clinical studies evaluating acute LCM use.
- Descriptive charting of data from included studies.
Main Results:
- Ten studies (5 preclinical, 5 clinical) were included.
- Preclinical studies assessed seizure, electrophysiological, histological, inflammatory, and behavioral outcomes.
- Clinical studies (RCTs, cohorts, case report) focused on seizure and safety outcomes, with limited neurological/functional assessment.
Conclusions:
- Current evidence supporting Lacosamide (LCM) use in acute traumatic brain injury (TBI) is limited.
- Discrepancies exist between outcome domains evaluated in preclinical versus clinical TBI research.
